Lucira Health, Inc.
LHDX
+434.6%
+ Free Alerts
shares are surging higher on Tuesday after the company announced it submitted an Emergency Use Authorization application to the FDA for over-the-counter use of its COVID-19 & Flu test.
What happened: Today, Lucira announced that it submitted an Emergency Use Authorization (EUA) application for its at-home molecular COVID-19 & Flu test kits. The company first received EUA for point-of-care use in a healthcare setting in November 2022.
The company’s kits test for COVID-19 and influenza, which the company noted, have similar symptoms but different treatments that are most effective early in an infection. The test aims to differentiate between the two viruses quickly.
Comments